ArticleSurgical case reports2026
Spontaneous Regression of Metastatic Colorectal Cancer Following Discontinuation of an Interleukin-6 Receptor Inhibitor: A Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSpontaneous cancer regression is exceptionally rare, particularly in colorectal cancer. Tumor regression has been reported in some patients with autoimmune diseases or organ transplants, after cessation of immunosuppressive therapy; however, its underlying mechanisms remain unclear. We report a rare case of Stage IVA transverse colon cancer with synchronous liver metastasis that showed complete pathological regression in both sites after discontinuation of tocilizumab, an interleukin-6 receptor inhibitor. CASE PRESENTATION: A 79-year-old woman with a history of rheumatoid arthritis and interstitial pneumonia was treated with iguratimod, methotrexate, prednisolone, and tocilizumab. PET-CT images revealed an accumulation of fluorodeoxyglucose in the transverse colon and liver. Colonoscopy and biopsy findings confirmed a poorly differentiated adenocarcinoma in the transverse colon; liver biopsy findings confirmed metastatic disease. In preparation for surgery, and because the rheumatoid arthritis activity was stable, tocilizumab was discontinued. Three months after tocilizumab discontinuation, laparoscopic partial colectomy with lymph node dissection was performed. Histopathologic examination of the resected colon showed no viable tumor cells. Subsequently, laparoscopic partial hepatectomy of segments 2 and 3 revealed no viable tumor cells as well. The patient remained recurrence-free at the 2-year follow-up.
conclusionsThe findings of this case suggest that tocilizumab discontinuation may have reactivated antitumor immune responses, resulting in spontaneous regression of both the primary colorectal cancer and liver metastasis. Notably, prior to regression, both masses were histologically confirmed as malignant lesions. This observation provides valuable clinical insight into the relationship between interleukin-6 receptor blockade, immune modulation, and tumor dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.